Integrated BioPharma FY2026 revenue falls 19.3% to $43.9M; swings to $2.8M net loss from $0.8M income

INTEGRATED BIOPHARMA INC

Q4 revenue $9.8M vs $14.2M a year earlier, down $4.4M or 31.0%; Q4 operating loss $0.9M vs $0.6M operating income.
FY2026 operating loss ~$2.7M vs FY2025 operating income $2.0M; Q4 gross profit collapsed to $28K from $1.47M.
FY net loss ~$2.8M (-$0.09/share) vs FY2025 net income ~$0.8M ($0.03/share); Q4 net loss ~$1.4M (-$0.04 vs -$0.01).
Co-CEOs Riva Sheppard and Christina Kay: two largest Contract Manufacturing customers were ~90% of FY2026 revenue, up from 84% in FY2025.
FY2026 income tax expense of $0.3M recorded despite pre-tax loss of $2.6M; weighted average shares 31.06M.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.